Steadybase.

Immunovant, Inc.

Website LinkedIn Latest 10-K
  • IMVT · Nasdaq
  • Biological Products, (No Diagnostic Substances)
  • Durham, NC
  • 315 employees
  • CIK 0001764013

Updated from SEC filings through

Top things to know

Executives

Immunovant, Inc. is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Durham, NC. It trades as IMVT on Nasdaq. It reported about 315 employees. Eric Venker is Chief Executive Officer.

Five-year financials

MetricFY2026FY2025FY2024FY2023FY2022
Revenue Not on file Not on file Not on file Not on file Not on file
Operating income Not on file Not on file Not on file Not on file Not on file
SG&A $76.2M
10-K, 2026-05-20
$77.2M
10-K, 2026-05-20
$57.3M
10-K, 2026-05-20
$48.0M
10-K, 2025-05-29
$54.2M
10-K, 2023-05-22
Net income -$506M
10-K, 2026-05-20
-$414M
10-K, 2026-05-20
-$259M
10-K, 2026-05-20
-$211M
10-K, 2025-05-29
-$157M
10-K, 2023-05-22

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Eric Venker, M.D., Pharm.D. Named in proxy
bio: Chief Executive Officer
DEF 14A, July 22, 2026
Eric Venker Eric Venker Chief Executive Officer Form 4, July 6, 2026
Tiago Girao Chief Financial Officer Form 4, July 24, 2026
Tuyl Christopher Van Chief Legal Officer Form 4, September 25, 2026
Melanie Gloria Melanie Gloria
Chief Operating Officer
Chief Operating Officer Form 4, August 21, 2026
Jay S. Stout
Chief Technology Officer at Immunovant
Chief Technology Officer Form 4, July 24, 2026
Christopher Van Tuyl, J.D. Christopher Van Tuyl, J.D. Named in proxy
bio: Chief Legal Officer and Corporate Secretary
DEF 14A, July 22, 2026
Michael Geffner Chief Medical Officer Form 4, October 24, 2025
Frank Torti Board member (per proxy)
bio: Director
DEF 14A, July 22, 2026
Andrew Fromkin Director 10-K, May 20, 2026
Atul Pande Director 10-K, May 20, 2026
Douglas Hughes Director 10-K, May 20, 2026
Jacob Bauer Director 10-K, May 20, 2026
Robert Susman Director 10-K, May 20, 2026

What Immunovant, Inc. does

Immunovant, Inc. (“Immunovant,” “we” or the “Company”) is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Our focus is on developing IMVT-1402 (imeroprubart), a potentially best-in-class inhibitor of the neonatal fragment crystallizable receptor (“FcRn”), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (“IgG”) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies.

Item 1. Business, 10-K for the year ending March 31, 2026

Shares and governance

Shares outstanding 206.9 million (as of November 3, 2026) 10-Q, November 9, 2026
Public float $1.3B (as of September 30, 2025) 10-K, May 20, 2026
Reportable segments 1 (period ending September 30, 2026) 10-Q, November 9, 2026
Latest proxy statement Meeting September 2, 2026 (filed July 22, 2026) DEF 14A, July 22, 2026
Auditor Ernst & Young LLP (Iselin, New Jersey) Latest 10-K

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
November 11, 2026 Atul Pande
Director
Sale 3,000 $108K Form 4, November 12, 2026
October 28, 2026 Tiago Girao
Chief Financial Officer
Sale 6,606 $188K Form 4, October 30, 2026
October 21, 2026 Jay S. Stout
Chief Technology Officer
Sale 2,595 $75K Form 4, October 23, 2026
October 7, 2026 Tuyl Christopher Van
Chief Legal Officer
Sale 1,327 $43K Form 4, October 9, 2026
October 7, 2026 Melanie Gloria
Chief Operating Officer
Sale 2,241 $72K Form 4, October 9, 2026
October 7, 2026 Jay S. Stout
Chief Technology Officer
Sale 3,809 $122K Form 4, October 9, 2026
October 2, 2026 Eric Venker
Chief Executive Officer
Sale 3,506 $120K Form 4, October 5, 2026
September 23, 2026 Tuyl Christopher Van
Chief Legal Officer
Sale 2,846 $103K Form 4, September 25, 2026

Recent 8-K events

Frequently asked questions about Immunovant, Inc.

What does Immunovant, Inc. do?
In its own words, from Item 1 of its 10-K: "Immunovant, Inc. (“Immunovant,” “we” or the “Company”) is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Our focus is on developing IMVT-1402 (imeroprubart), a potentially best-in-class inhibitor of the neonatal fragment crystallizable receptor (“FcRn”), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (“IgG”) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies."
How many employees does Immunovant, Inc. have?
About 315 as of March 31, 2026, as stated in its annual report.
Who is the CEO of Immunovant, Inc.?
Eric Venker, Chief Executive Officer, as named in a 4 filed July 6, 2026.
Who is the CFO of Immunovant, Inc.?
Tiago Girao, Chief Financial Officer, as named in a 4 filed July 24, 2026.
Where is Immunovant, Inc. headquartered?
Durham, NC.
What is Immunovant, Inc.'s stock ticker?
IMVT on Nasdaq.
What industry is Immunovant, Inc. in?
Biological Products, (No Diagnostic Substances), SIC code 2836.
What is Immunovant, Inc.'s website?
immunovant.com.
When does Immunovant, Inc. report earnings next?
February 8, 2027. This is an estimate from past filing dates, not a confirmed date.
Is Immunovant, Inc. a public company?
Yes. Immunovant, Inc. files with the SEC under CIK 0001764013 and trades as IMVT.
Who audits Immunovant, Inc.?
Ernst & Young LLP, Iselin, New Jersey, as named in its latest annual report (10-K).
How many shares of Immunovant, Inc. are outstanding?
206.9 million shares as of November 3, 2026, from its 10-Q filed November 9, 2026.
What is Immunovant, Inc.'s public float?
$1.3B as of September 30, 2025, as reported on the cover of its 10-K filed May 20, 2026.
How many business segments does Immunovant, Inc. report?
1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 9, 2026.
When is Immunovant, Inc.'s annual shareholder meeting?
September 2, 2026, per its proxy statement (DEF 14A) filed July 22, 2026.
Have Immunovant, Inc. insiders traded stock recently?
Since July 9, 2025, officers and directors reported 50 open-market sales worth about $16.9M and 1 purchase worth about $350M on Forms 4 and 5. The most recent: Atul Pande (Director) sold 3,000 shares on November 11, 2026.